USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
BIOLINK LIFE SCIENCES, INC.
Address:
250 QUADE DRIVE
CARY, NC 27513-
Phone:
(919) 678-9478
URL:
N/A
EIN:
562264277
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $602,215.00 6
STTR Phase I $194,509.00 1

Award List:

Novel Pro-Dyes to Expand Use of the VerifEYE Contamination Detection System

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$79,031.00
Agency:
USDA
Principal Investigator:
Abstract:
Bacterial contamination in the American beef supply continues to be a serious concern for the meat processing industry. As part of a broad program of improvements in processing procedures and sanitary methods, meat processors in the U.S. and abroad have initiated use of the VerifEYET Carcass… More

Stability of new, iron-replete total nutrient admixtures

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$105,364.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): There has been little progress in the treatment of iron deficiency anemia using a parenteral nutrient (PN) admixture with lipids as a suitable drug delivery vehicle. Currently approved parenteral iron colloids (e.g., iron dextrans) destabilize total nutrient… More

Soluble Ferric Pyrophosphate: A Novel Iron Source for Individuals With High Iron Needs

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$79,590.00
Agency:
USDA
Principal Investigator:
Abstract:
Iron (Fe) deficiency is the worlds most prevalent nutrient deficiency and causes both significant adverse health effects and enormous economic losses globally. Several groups, including infants, children, young women, the elderly, and those with chronic diseases remain vulnerable to Fe deficiency,… More

Novel Phosphate Binder: Effects on Hyperphosphatemia, Vascular Calcification and Bo

Award Year / Program / Phase:
2010 / STTR / Phase I
Award Amount:
$194,509.00
Agency:
HHS
Principal Investigator:
Deanna J. Nelson – 919-678-9478
Research Institution:
Washington University
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): In patients with chronic kidney disease (CKD), phosphate retention may contribute to progression of renal failure and is a major factor in the development of secondary hyperparathyroidism and vascular calcification. Progression of injury is causally associated… More

SBIR TOPIC NCCAM: 001 R AND RS-ALPHA-LIPOIC ACID ANALYTICAL METHODS VALIDATION

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$146,080.00
Agency:
HHS
Principal Investigator:
Deanna Nelson – 919-678-9478
Abstract:
Not Available

Enhanced hemoglobin production in neonatal piglets with FCP, a low molecular weight iron chelate

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$97,215.00
Agency:
USDA
Principal Investigator:
Deanna J. Nelson, Chief Scientific Officer – 919-678-9478
Abstract:
The modernization of the US swine industry has been critical to the sustainability and global competitiveness of US swine production. At the same time, modernization has also required dramatic changes in animal management. By housing pigs indoors, producers have caused the unintended problem of iron… More

Low Molecular Weight Iron Chelate for Treatment of Anemia of Inflammation

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$94,935.00
Agency:
HHS
Principal Investigator:
Deanna J. Nelson – 919-678-9478
Abstract:
DESCRIPTION (provided by applicant): Patients with chronic anemia (i.e., anemia of inflammation) frequently find that iron repletion cannot be achieved with oral iron fortificants. The current standard of care for these patients is infusion of intravenous(IV) iron-carbohydrate complexes. These… More